Similarly on August 7, Needham analyst Alan Carr reiterated a Buy rating on Intercept with a $500 price target, noting, "The company submitted an NDA for Obeticholic Acid (OCA) in Primary Billiary Cirrhosis in late June 2015. A response from the agency regarding filing and priority review is expected this month. We assume approval and launch in late 1Q16."
Andrew Berens of Morgan Stanley initiated coverage of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with an Underperform rating and $165 price target, marking one of the analyst's "highest-conviction, out-of-consensus calls."
According to Berens, an upcoming review of the company's lead candidate OCA could provide new data and insight into the drug's adverse lipid effects which increases perceptions of risk and hurts its commercial viability.
9:48 am ET August 10, 2015
Intercept Pharmaceuticals is known for developing drugs to treat liver disease. The company's pipeline drug is called Obeticholic acid, or OCA, and is used to treat patients with the liver disease Primary Biliary Cirrhosis (PBC).
Intercept announced on June 29 that it had completed a New Drug Application (NDA) for OCA to treat PBC. The drug received fast-track designation in the United States and orphan drug designation in both the U.S. and Europe. Investors are hoping that the FDA will announce their decision of whether they approve or deny OCA this week. Article written August 10.
Wedbush analyst Liana Moussatos believes "the FDA could provide confirmation of a Q1:16 advisory committee meeting and PDUFA date" for OCA and "anticipate[s] this announcement could provide a catalyst for the stock." The analyst sees the drug launching "in H1 2016 and project[s] WW peak sales could reach $2.26BN in 2022." Moussatos reiterated an Outperform rating on Intercept on August 7 with a fair value estimate of $493.
On average, Liana Moussatos has a 42% success rate recommending stocks and a +23.2% average return per recommendation when measured over a one-year horizon. She has rated Intercept 21 times since 2009, earning a 40% success rate recommending the stock and a +59% average return per recommendation.
Similarly on August 7, Needham analyst Alan Carr reiterated a Buy rating on Intercept with a $500 price target, noting, "The company submitted an NDA for Obeticholic Acid (OCA) in Primary Billiary Cirrhosis
I'm not so sure about 260 on FDA acceleration. Could be mostly non-event. Most worried that there will be delay on decision by FDA. What's your opinion? Will they make a decision by the end of the week?
It is supposed to be this week or will it be put off for a long time? Anybody care to guess? I'm gambling that it will be by this weeks end, Anyone else buyng options around event?
I thought the results were pathetic. It was in solid tumors, but compare that to our competitors like JUNO, IMDZ and some of the immunotherapy stocks. It looks like they can eradicate cancers fully and that cancer is presenting antigen that the immune system can recognize and attack. Cancer becomes the same as getting rid of a cold for the immune system. Complete and efficient removal just like the immune system is designed to do through years of evolution.
What were the figures a response in 14% and partial in 41%? CALA and AGIO just aren't going to be able to compete.
It's hard to remember but weren't you leading the charge against the shorters when they switched from trying to take down QCOR to MNK and MNK went down to 55, i think you said you were buying all you could +some options.
You can't be doing all that bad. Better than Jonx?
Ohh now I'm angry. At least I have a sack, nuttless. At least I'm not jealous of Cait and her new boobs like you are.
Right and you talked about million dollar trades at 26, 50, right before the buyout. Constant braggin about short trades at the top that day only to see the stock much higher.a day or week later.
We'd rather light a candle than have you curse the darkness. You're the only guy on the QCOR board who had so many failed suicide attempts.
You should always take our advice.
This is more to get JONX to short the stock so I can make some real money, but since you guys are still my favorite board check out avxl. (He follows me around because he enjoys punishment.) Science is sound for AVXL compound, all that's left is the clinic. They have whole different mechanism than other ALZ drugs, all have failed their recent trials Pretty large market plus mechanism translates to other diseases. Favorite selling point is they were a failed digital photo company now trying their hand at biotech and medical research. Straight up risk takers only, GOD I love America. Plus they're Greeks which means they at least went to college although who knows if any actually graduated as fraternities don't always emphasize academics.
MNK bores me plus I'm #$%$ because they got QCOR for a cheap price so I stopped following it. Anyone fill me in whether it's worth doing DD at these prices?
Now the infirm is claiming to belong to a "firm" Heh,heh!?
You'll never make back all the money you lost on QCOR.
In the first presentation Tangui Maurice, PhD, a member of the Anavex Scientific Advisory Board, demonstrated for the first time the essential role of sigma-1 receptor (S1R) through S1R KO (knock out) on survival and memory in the presence of amyloid. In the transgenic amyloid expressing mouse model Tg2576, where the sigma-1 receptor (S1R) expression is impaired through S1R KO (knock out), at 12 months the survival was reduced by 50% compared to the non-S1R KO Tg2576 model. Apparently the genetic inactivation of the S1R gene worsens amyloid toxicity and has a detrimental impact on survival and also memory impairment. Amyloid is believed to play a key role in the development of the symptoms of Alzheimer's disease (AD). On the other hand, activation of the S1R through treatment with the S1R agonist ANAVEX 2-73 in the Tg2576 model alleviates amyloid toxicity and resulting learning deficits both after one month and two months daily oral treatment, respectively. In addition expression of ROS (reactive oxidative species) as well as plasticity related IEG and transcription factors in the mouse hippocampus were clearly negatively impacted through the S1R KO, however, were significantly improved through ANAVEX 2-73. This confirms that targeting the S1R, a key factor in brain plasticity, may demonstrate neuroprotection in Alzheimer's disease. ANAVEX 2-73 is currently undergoing a Phase 2a trial in Alzheimer's patients.Apparently the genetic inactivation of the S1R gene worsens amyloid toxicity and has a detrimental impact on survival and also memory impairment. Amyloid is believed to play a key role in the development of the symptoms of Alzheimer's disease (AD). On the other hand, activation of the S1R through treatment with the S1R agonist ANAVEX 2-73 in the Tg2576 model alleviates amyloid toxicity and resulting learning deficits both after one month and two months daily oral treatment, respectively. In addition expression of ROS (reactive oxidative species) as well as plast
Buy his book, market strategy based on premarket futures- lose money and be a hoser at the same time